ReviewWorld journal of urology2020
Evidence-based approach to active surveillance of prostate cancer.
Review in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Canadian Prostate Cancer Trends in the Context of PSA Screening Guideline Changes.Current oncology (Toronto, Ont.) · 2025Article
- Patient Reported Outcomes and Treatment-Associated Complications as a Consideration in Selecting Localized Prostate Cancer Management.Research and reports in urology · 2025Review
- Intraobserver and Interobserver Agreement between Six Radiologists Describing mpMRI Features of Prostate Cancer Using a PI-RADS 2.1 Structured Reporting Scheme.Life (Basel, Switzerland) · 2023Article
- Ultra-high-field MR in Prostate cancer: Feasibility and Potential.Magma (New York, N.Y.) · 2022Review
- A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance.BMC urology · 2021Article
- Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.BMC medicine · 2020Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Active surveillance is a good management option for some men with non-metastatic prostate cancer. In this review, we examine the evidence for several topics related to active surveillance. We examine: (1) which patients should be eligible for active surveillance, (2) what follow-up (monitoring) protocols should be used for men on surveillance, (3) what is the role of prostate magnetic resonance imaging (MRI) for men on surveillance, and (4) what is the prognosis for men who choose surveillance compared to radical treatment. In many instances, the evidence is evolving or lacking. In these situations, we highlight the limitations of the data.
Indexed as
Identifiers
30726506What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.